{"name":"Chromaderm, Inc.","slug":"chromaderm-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Ruboxistaurin mesylate","genericName":"Ruboxistaurin mesylate","slug":"ruboxistaurin-mesylate","indication":"Diabetic macular edema (DME)","status":"phase_3"}]}],"pipeline":[{"name":"Ruboxistaurin mesylate","genericName":"Ruboxistaurin mesylate","slug":"ruboxistaurin-mesylate","phase":"phase_3","mechanism":"Ruboxistaurin mesylate is a protein kinase C (PKC) beta inhibitor that reduces vascular permeability and inflammation in diabetic microvascular complications.","indications":["Diabetic macular edema (DME)","Diabetic retinopathy"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxQNGhYTW5hX3kxZ2YwWV8tQXg0OHRkR2dtbkM3TDVQNlY5NzloQWJxTmRRbkRLMExHSTZlbHFySTNlUmJVWjk4X3JZanBRaW9wTFIyeDRjNHp0cHZuVUQ2RFl1V2NEVEV4UzY4bzJSc1JEN1BFWEctWC1KY0ZRUXMyOFhELU9QOXVnYjAwMUNRbHpSSlhxdlBfWWlCaTJJdW8yOHpvc2hNbDZxUQ?oc=5","date":"2022-10-26","type":"pipeline","source":"Fierce Biotech","summary":"Recursion reprioritizes, dumping rare disease asset while raking in $150M - Fierce Biotech","headline":"Recursion reprioritizes, dumping rare disease asset while raking in $150M","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi-gFBVV95cUxObjN6V2t5c2lVOEYxYU8xYmpudnJtRW9fTlBaOEhldlA0Y3R2UVFhQTdKUnVBVGpobTN2ODJWSXhRSUZPcHZvdHNBQ0NXRzNqTHB0cHREWThKSFhUdmdvTWdjRHdtOTlrclFPcWJ1bEM4b3JnbUU4dzA1YlpCNWxKaHVyLWxlNE5vOUU0S01EY1loUUZKZEZyUUVQUEFJelZ0Mkw3RzVpSzhtM0FuYW05bUJ2V01NVE5rNXo3QWREckNaeFpHLXhUOUpWVzRSeDJSd29nc29QUDRrSmx5NzlyeTZESWRKRkNXRVdMZGlkTU9tUGdIN0diUUd3?oc=5","date":"2021-12-21","type":"deal","source":"Business Wire","summary":"DermBiont Raises $28 Million and Acquires Chromaderm to Expand Targeted Topical Therapeutics in Development - Business Wire","headline":"DermBiont Raises $28 Million and Acquires Chromaderm to Expand Targeted Topical Therapeutics in Development","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}